NCT07268703Not yet recruiting
Expiratory Muscle Training in Parkinson's Disease With Forward Trunk Flexion
Effect of Expiratory Muscle Strength Training in Patients With Parkinson's Disease and Forward Trunk Flexion: A Pilot Study
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
Postural abnormalities (PA) negatively affecting the axial system are part of the symptoms of Parkinson's disease (PD). They occur in more than 20% of patients with PD especially in more advanced stages of the disease, contribute significantly to patient disability, affect respiratory functions, and reduce quality of life. Eighty-five percent of patients with forward trunk flexion (FTF) reported difficulties with swallowing (dysphagia), shortness of breath, and drooling. Previous studies in patients with PD also identified cough disorders (dystussia). Since cough and properly functioning swallowing are key mechanisms for airway protection, impairments in these functions lead to a higher risk of aspiration. The seriousness of this problem is clearly confirmed by the fact that aspiration pneumonia is the leading cause of death in patients with PD. Among non-pharmacological interventions for airway protection, expiratory muscle strength training (EMST) has been shown to be beneficial in patients with PD. Recent randomized controlled studies demonstrated a significant effect of EMST on dysphagia, dystussia, drooling, and dysarthria in patients with PD. However, the literature lacks data on the effect of EMST on dystussia in patients with PD and FTF, who, according to previous research, are also affected by restrictive ventilatory impairment, which negatively affects respiratory capacity and, in particular, cough strength. The aim of this study is to evaluate the effect of EMST on cough, swallowing, respiratory muscle strength, and drooling in patients with PD and forward trunk flexion.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- First submitted
- 25 Nov 2025
- Start date
- Dec 2025
- Primary completion date
- Mar 2026
- Lead sponsor
- General University Hospital, Prague
- Diseases
- Parkinson disease
- NCT number
- NCT07268703
What you commit to
- Study type: Interventional
- Planned participants: 28
- From Dec 2025 to the primary completion date, Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Change in antiparkinsonian medication within the last 3 months prior to study enrollment
Other
- Other neurological, orthopedic, cardiovascular, or respiratory comorbidities
- Inability to cooperate due to neuropsychological dysfunction
- Current smoking history
- Inadequate lip seal
Who the study is looking for
- Diagnosis of Parkinson' s disease
- Age ≥ 18 years
- MoCA score (Montreal Cognitive Assessment) ≥ 19
- Score II-IV during the "ON" phase under regular antiparkinsonian medication according to the Modified Hoehn and Yahr Scale
- Pathological forward trunk flexion defined as thoracic (≥ 25°) or lumbar flexion (\> 15°) during standing and walking, which completely disappears in the supine position (for the experimental group only)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| General University Hospital Coordinator of this site? Confirm its status | Prague | Czechia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.